Nanobiotix S.A.
NASDAQ: NBTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurent Levy
- Employees
- 108
- Headquarters
- Paris, France
- IPO year
- 2020
- Market cap
- $1.7B
- Website
- https://www.nanobiotix.com
Loading NBTX…
Loading profile data…Frequently asked questions about NBTX
What does Nanobiotix S.A. (NBTX) do?
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad...
Where does NBTX trade?
Nanobiotix S.A. (NBTX) trades on the NASDAQ Global Select.
What sector is NBTX in?
Nanobiotix S.A. (NBTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nanobiotix S.A.?
Laurent Levy is the chief executive officer of Nanobiotix S.A. (NBTX).
Where is Nanobiotix S.A. headquartered?
Nanobiotix S.A. is headquartered in France.
Does NBTX pay a dividend?
Nanobiotix S.A. (NBTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NBTX go public?
Nanobiotix S.A. (NBTX) completed its initial public offering in 2020.
Is NBTX an ADR?
Yes — NBTX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Nanobiotix S.A. reporting and dividends follow the underlying issuer.